Death due to breathing difficulties associated with hereditary angioedema (HAE) remains a concern in Brazil, highlighting that misdiagnosis and a lack of treatment access in lower-income countries may contribute to increased mortality rates, a recent study highlights. While HAE-associated deaths have declined significantly in recent years within high-income countries,…
The first case of a patient developing angioedema accompanied by hives after treatment with solifenacin, a medication commonly used to treat urinary incontinence, was described in a recent case report. The report, “Solifenacin-induced acute urticaria and angioedema: a rare adverse effect,” was published in the Postgraduate Medical…
Long-term preventive (prophylactic) treatment with Haegarda is safe, decreases how often swelling attacks occur in patients with hereditary angioedema (HAE), and how often they rely on rescue medications to treat swelling attacks. These findings come from an open-label extension study (NCT02316353) of the Phase 3 COMPACT trial…
KVD900, KalVista Pharmaceuticals’ investigational on-demand treatment for swelling attacks in people with hereditary angioedema (HAE), will now be called sebetralstat, the company announced. Sebetralstat will become the nonproprietary nomenclature for the treatment’s active ingredients, meaning that will be the generic name for any medication using the same formulation…
A new hereditary angioedema (HAE) registry, touted as the first of its kind, is using real-world data to provide comprehensive insights into patients’ journeys. The Trio-CIIC HAE Registry derives from a partnership between real-world data provider Trio Health and the Consortium of Independent Immunology Clinics (CIIC), a professional organization…
Lack of awareness about rare diseases, such as hereditary angioedema (HAE), contributes to their often long and delayed diagnosis, a study suggests. The study, “Why does it take so long for rare disease patients to get an accurate diagnosis?—A qualitative investigation of patient experiences of hereditary angioedema,” was…
Intellia Therapeutics has completed dosing the first group of patients enrolled in a Phase 1/2 clinical trial testing its gene-editing therapy, NTLA-2002, for the treatment of hereditary angioedema (HAE). In the Phase 1 part of the study (NCT05120830), patients will receive a single infusion of NTLA-2002, delivered into…
HAE Awareness Day is observed around the world each May 16 to bring attention to hereditary angioedema (HAE) and those people the disorder affects. The goal is to heighten awareness among the general public, as well as healthcare professionals, decision-makers, and industry representatives. The theme for this year’s observance…
A Russian military plane crash near Tetiana Zamorska’s home in Kyiv, Ukraine, was a sign that it was time for her and her family to leave. The treacherous, 34-hour pilgrimage that ultimately brought the group of eight by car to temporary accommodations in neighboring Poland last month was physically and emotionally difficult,…
Takeda Canada has won a bid making it Héma-Québec’s sole source of Takhzyro (lanadelumab) — an approved under-the-skin treatment to prevent attacks of hereditary angioedema (HAE) — through at least 2024. Takhzyro is now available as a prophylaxis treatment for people with HAE in Québec, according to…
Get regular updates to your inbox.
